Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty‐eight patients H Poormoghim, M Lucas, N Fertig, TA Medsger Jr Arthritis & Rheumatism: Official Journal of the American College of …, 2000 | 380 | 2000 |
Systemic sclerosis: Comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement—A retrospective study H Poormoghim, N Rezaei, Z Sheidaie, AR Almasi, M Moradi-Lakeh, ... Rheumatology international 34, 1691-1699, 2014 | 46 | 2014 |
Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis H Poormoghim, M Moradi Lakeh, M Mohammadipour, F Sodagari, ... Rheumatology international 32, 2431-2444, 2012 | 46 | 2012 |
KIR3DL1+HLA‐B Bw4 Ile80 and KIR2DS1+HLA‐C2 combinations are both associated with ankylosing spondylitis in the Iranian population N Tajik, F Shahsavar, H Poormoghim, MF Radjabzadeh, T Mousavi, ... International journal of immunogenetics 38 (5), 403-409, 2011 | 46 | 2011 |
The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort MG Lazzaroni, E Marasco, C Campochiaro, J DeVries-Bouwstra, ... Rheumatology 60 (11), 5028-5041, 2021 | 45 | 2021 |
Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study VK Jaeger, M Tikly, D Xu, E Siegert, E Hachulla, P Airò, G Valentini, ... Rheumatology 59 (7), 1684-1694, 2020 | 39 | 2020 |
Inhibitory killer cell immunoglobulin-like receptor KIR3DL1 in combination with HLA-B Bw4iso protect against ankylosing spondylitis T Mousavi, H Poormoghim, M Moradi, N Tajik, F Shahsavar, B Asadifar Iranian Journal of Immunology 7 (2), 88-95, 2010 | 32 | 2010 |
Phenotypic study of natural killer cell subsets in ankylosing spondylitis patients T Mousavi, H POURMOGHIM, M MORADI, N Tajik, F Shahsavar, M SOUFI IRANIAN JOURNAL OF ALLERGY, ASTHMA AND IMMUNOLOGY (IJAAI) 8 (4), 193-198, 2009 | 32 | 2009 |
Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients H Poormoghim, AS Moghadam, M Moradi-Lakeh, M Jafarzadeh, ... Rheumatology international 33, 1943-1950, 2013 | 31 | 2013 |
Primary hypertrophic osteoarthropathy H Poormoghim, A Hosseynian, A Javadi Rheumatology international 32 (3), 607-610, 2012 | 22 | 2012 |
Survival and causes of death in systemic sclerosis patients: a single center registry report from Iran H Poormoghim, E Andalib, A Jalali, A Ghaderi, A Ghorbannia, ... Rheumatology international 36, 925-934, 2016 | 21 | 2016 |
Gene expression profiling of toll-like receptor 4 and 5 in peripheral blood mononuclear cells in rheumatic disorders: ankylosing spondylitis and rheumatoid arthritis S Almasi, S Aslani, H Poormoghim, AR Jamshidi, S Poursani, ... Iranian Journal of Allergy, Asthma and Immunology, 87-92, 2016 | 17 | 2016 |
Systemic sclerosis and calcinosis cutis: response to rituximab. H Poormoghim, E Andalib, AR Almasi, E Hadibigi Journal of Clinical Pharmacy & Therapeutics 41 (1), 2016 | 15 | 2016 |
Preliminary study of cardiovascular manifestations and cardiac severity scale in 58 patients with systemic sclerosis in Iran using the Medsger scale H Poormoghim, MA Poorkarim, MM Lakeh, BN Heshmati, S Almasi, ... The Journal of Tehran Heart Center 5 (1), 14, 2010 | 12 | 2010 |
Progesterone aggravates lung fibrosis in a mouse model of systemic sclerosis F Vafashoar, K Mousavizadeh, H Poormoghim, A Haghighi, ... Frontiers in Immunology 12, 742227, 2021 | 11 | 2021 |
MiR-27a as a diagnostic biomarker and potential therapeutic target in systemic sclerosis P Bayati, M Kalantari, MA Assarehzadegan, H Poormoghim, N Mojtabavi Scientific Reports 12 (1), 18932, 2022 | 10 | 2022 |
Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region A Lescoat, D Huscher, N Schoof, P Airò, J de Vries-Bouwstra, ... Rheumatology 62 (6), 2178-2188, 2023 | 9 | 2023 |
Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort M Elhai, N Sritharan, M Boubaya, A Balbir-Gurman, E Siegert, E Hachulla, ... The Lancet Rheumatology 4 (11), e785-e794, 2022 | 8 | 2022 |
Cohort enrichment strategies for progressive interstitial lung disease in systemic sclerosis from European Scleroderma Trials and Research AM Hoffmann-Vold, C Brunborg, P Airò, LP Ananyeva, L Czirják, ... Chest 163 (3), 586-598, 2023 | 7 | 2023 |
Aberrant expression of miR-138 as a novel diagnostic biomarker in systemic sclerosis P Bayati, H Poormoghim, N Mojtabavi Biomarker Insights 17, 11772719221135442, 2022 | 7 | 2022 |